Latest news with #ProMISNeurosciences
Toronto Star
28-07-2025
- Business
- Toronto Star
ProMIS Neurosciences Announces Private Placement Financing
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 28, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that it has entered into a purchase agreement (the 'Purchase Agreement') with existing institutional and accredited investors to issue and sell an aggregate of approximately $3.0 million of warrants (the 'Warrants'). The Warrants were sold at a price of $0.1875 per share through a private investment in public equity ('PIPE') financing. The Warrants have an exercise price of $1.25 per Warrant Share, are immediately exercisable and will expire five years from the date of initial issuance. The PIPE financing included participation from existing institutional investors, including Ally Bridge Group. ARTICLE CONTINUES BELOW ProMIS anticipates the gross proceeds from the PIPE financing to be approximately $3.0 million, before deducting fees and other offering expenses payable by the Company. In conjunction with the proceeds from the exercise of existing warrants, the total gross proceeds to the Company inclusive of the PIPE Offering will be approximately $12.0 million. The PIPE financing is expected to close on July 29, 2025, subject to customary closing conditions. Proceeds from the PIPE financing are expected to be used to advance the clinical development of PMN310, ProMIS' lead therapeutic candidate, as well as for working capital and other general corporate expenses. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended ('Securities Act'), or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. ProMIS Neurosciences has agreed to file a registration statement with the SEC registering the resale of the Common Shares issuable upon the exercise of the Warrants issued in the PIPE financing. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or other jurisdiction. About ProMIS Neurosciences Inc. ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, predicts novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN). Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, 'forward-looking information') within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as 'plans', 'excited to', 'targets', 'expects' or 'does not expect', 'is expected', 'an opportunity exists', 'is positioned', 'estimates', 'intends', 'assumes', 'anticipates' or 'does not anticipate' or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur' or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the expected timing for the closing of the PIPE financing and the anticipated use of proceeds from the PIPE financing. Statements containing forward-looking information are not historical facts but instead represent management's current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that clinical results or early results may not be indicative of future results, the Company's ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the 'Risk Factors' section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2024 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. For further information: ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW Please submit media inquiries to info@ For Investor Relations, please contact: Kaytee Bock Zafereo
Globe and Mail
25-07-2025
- Business
- Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProMIS Neurosciences (PMN – Research Report) and Bruker (BRKR – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. ProMIS Neurosciences (PMN) In a report issued on July 21, Thomas Shrader from BTIG maintained a Buy rating on ProMIS Neurosciences, with a price target of $8.00. The company's shares closed last Thursday at $0.89, close to its 52-week low of $0.62. According to Shrader is a 1-star analyst with an average return of -0.2% and a 35.4% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Coya Therapeutics, Inc., and Arcturus Therapeutics. ;'> Currently, the analyst consensus on ProMIS Neurosciences is a Strong Buy with an average price target of $5.00, a 488.2% upside from current levels. In a report issued on July 14, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $4.00 price target. Bruker (BRKR) Leerink Partners analyst Puneet Souda maintained a Buy rating on Bruker on July 21 and set a price target of $65.00. The company's shares closed last Thursday at $40.27. According to Souda 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.3% and a 30.5% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. ;'> Currently, the analyst consensus on Bruker is a Moderate Buy with an average price target of $52.33, a 31.3% upside from current levels. In a report issued on July 19, TR | OpenAI – 4o also upgraded the stock to Buy with a $45.00 price target.
Business Insider
22-07-2025
- Business
- Business Insider
Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today?
ProMIS Neurosciences (PMN) stock surged on Monday after the precision medicine solutions company was granted Fast Track designation for PMN310 by the U.S. Food and Drug Administration (FDA). This is a therapeutic candidate in development at the company to treat Alzheimer's disease. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. ProMIS Neurosciences noted that PMN310 is currently undergoing a Phase 1b trial evaluating its safety, tolerability, pharmacokinetics, and disease-relevant biomarkers in patients with early Alzheimer's disease. The company expects interim results from this trial in Q2 2026 and final results in Q4 2026. PMN stock was up 177.21% in pre-market trading on Monday, following a 6.38% drop on Friday. The stock has also decreased 53.67% year-to-date and 77.2% over the past 12 months. With today's rally came heavy trading, with more than 79 million shares traded, compared to a three-month daily average of about 3.5 million shares. Is ProMIS Neurosciences Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for ProMIS Neurosciences is Moderate Buy, based on two Buy ratings over the past three months. With that comes an average PMN stock price target of $3.50, representing a potential 695.27% upside for the shares.
The Market Online
21-07-2025
- Business
- The Market Online
Alzheimer's stock triples after FDA Fast-Track Designation
ProMIS Neurosciences (NASDAQ:PMN), a clinical-stage biotech stock focused on neurodegenerative diseases, has been granted the U.S. Food and Drug Administration's Fast-Track Designation for PMN310, its lead monoclonal antibody treatment for Alzheimer's disease The treatment is designed to offer a more targeted response compared to legacy options, reducing common side effects including brain swelling and bleeding known as amyloid-related imaging abnormalities (ARIA) ProMIS is a clinical-stage biotechnology stock focused on developing treatments against neurodegenerative and other misfolded protein diseases The Alzheimer's stock is up by 213.70 per cent on the news trading at US$1.38 as of 11:04 am ET, but has given back 28.47 per cent year-over-year and 85.15 per cent since 2020 ProMIS Neurosciences (NASDAQ:PMN), a clinical-stage biotech stock focused on neurodegenerative diseases, has been granted the U.S. Food and Drug Administration's (FDA) Fast-Track Designation for PMN310, its lead monoclonal antibody treatment for Alzheimer's disease. This content has been prepared in collaboration with ProMIS Neurosciences Inc., and is intended for informational purposes only. The treatment is designed to offer a more targeted response compared to legacy options, reducing common side effects including brain swelling and bleeding known as amyloid-related imaging abnormalities (ARIA). The designation expedites therapeutic development for serious conditions through easier access to the FDA, de-risking PMN310's path to market, which the Alzheimer's Association estimates at 7 million patients in the U.S. alone. PMB310 showed early promise in a phase 1a trial, demonstrating favorable safety and tolerance profiles, in addition to an efficient crossing of the blood-brain barrier in healthy volunteers. ProMIS' ongoing PRECISE-AD phase 1b trial is studying the effects of PMN310 in patients with early Alzheimer's disease, with eyes on characterizing safety, tolerability, pharmacokinetics and disease-relevant biomarkers. Interim six-month biomarker reporting is expected in Q2 2026 followed by final results in Q4. Leadership insights 'This is a pivotal moment for ProMIS and the Alzheimer's community, as receiving Fast-Track Designation not only underscores the potential of PMN310 to address a critical unmet need, but also provides valuable opportunities for regulatory insight as we advance towards key clinical milestones,' Neil Warma, ProMIS Neurosciences' president and chief executive officer, said in a statement. 'We designed PMN310 with a goal of providing Alzheimer's patients with a safer and more efficacious treatment option, which we believe represents the next generation of Alzheimer's therapeutics. By selectively targeting only the most harmful, toxic forms of amyloid-beta, we believe PMN310 has the potential to reduce the serious side effects seen with current Alzheimer's treatments, namely brain swelling and bleeding known as ARIA, while also delivering improved therapeutic benefit to patients.' About ProMIS Neurosciences ProMIS is a clinical-stage biotechnology stock focused on developing treatments against neurodegenerative and other misfolded protein diseases. The Alzheimer's stock (NASDAQ:PMN) is up by 213.70 per cent on the news trading at US$1.38 as of 11:04 am ET. The stock has given back 28.47 per cent year-over-year and 85.15 per cent since 2020. Join the discussion: Find out what investors are saying about this Alzheimer's stock on the ProMIS Neurosciences Inc. Bullboard and check out the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
Globe and Mail
14-07-2025
- Business
- Globe and Mail
Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
"Multiple System Atrophy Clinical Trials" Multiple System Atrophy companies are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others. (Albany, United States) 'Multiple System Atrophy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple System Atrophy Market. As per DelveInsight's assessment, globally, Multiple System Atrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Multiple System Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details Request for sample report to know in detail about drugs and companies in pipeline @ Multiple System Atrophy Pipeline Outlook Some of the key takeaways from the Multiple System Atrophy Pipeline Report: Multiple System Atrophy Companies across the globe are diligently working toward developing novel Multiple System Atrophy treatment therapies with a considerable amount of success over the years. Multiple System Atrophy companies working in the treatment market are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others, are developing therapies for the Multiple System Atrophy treatment Emerging Multiple System Atrophy therapies in the different phases of clinical trials are- NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others are expected to have a significant impact on the Multiple System Atrophy market in the coming years. are expected to have a significant impact on the Multiple System Atrophy market in the coming years. In May 2025, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity' or 'the Company'), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy (MSA). This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative approach to address the high unmet need for treating MSA, a disease with no approved therapy. In February 2025, H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA). In December 2024, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on creating disease-modifying therapies for neurodegenerative disorders, announced that the final participant in its ATH434-201 Phase 2 trial has completed the study. This randomized, double-blind, placebo-controlled trial targets early-stage multiple system atrophy (MSA). With this milestone reached, topline results are anticipated by late January or early February 2025. Multiple System Atrophy Overview Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by Multiple System Atrophy autonomic dysfunction, Multiple System Atrophy parkinsonism, and Multiple System Atrophy cerebellar ataxia. Multiple System Atrophy symptoms often include orthostatic hypotension, urinary incontinence, tremors, bradykinesia, muscle rigidity, gait imbalance, and coordination problems. Multiple System Atrophy diagnosis typically relies on clinical evaluation supported by MRI findings, which may show putaminal or cerebellar atrophy, although no definitive test exists. Multiple System Atrophy pathology reveals glial cytoplasmic inclusions containing alpha-synuclein, distinguishing it from similar disorders. Multiple System Atrophy progression is usually rapid, leading to severe disability within a few years of onset. Multiple System Atrophy treatment remains symptomatic, aiming to manage blood pressure fluctuations, motor symptoms, and urinary issues. While Multiple System Atrophy levodopa responsiveness is often poor compared to Parkinson's disease, some patients may experience temporary benefit. Multiple System Atrophy prognosis is generally poor, with an average survival of 6 to 10 years post-diagnosis. Ongoing Multiple System Atrophy research explores neuroprotective agents and disease-modifying therapies. Multiple System Atrophy awareness is essential for early recognition and multidisciplinary care to optimize patient quality of life. Get a Free Sample PDF Report to know more about Multiple System Atrophy Pipeline Therapeutic Assessment- Emerging Multiple System Atrophy Drugs Under Different Phases of Clinical Development Include: NM-402: Neuramedy Co.,Ltd Neuramedy Co.,Ltd PMN442: ProMIS Neurosciences ProMIS Neurosciences ENT-01: Enterin Inc. Enterin Inc. NC-2500: Nippon Chemiphar Nippon Chemiphar CS10BR05: CORESTEM, Inc CORESTEM, Inc AAV2-GDNF: Brain Neurotherapy Bio, Inc. Brain Neurotherapy Bio, Inc. KM-819: Kainos Medicines Kainos Medicines ATH434: Alterity Therapeutics Alterity Therapeutics Lu AF82422: H. Lundbeck A/S H. Lundbeck A/S Verdiperstat: Biohaven, Ltd Biohaven, Ltd Ampreloxetine: Selecta Biosciences Inc Selecta Biosciences Inc ION464: Ionis Pharmaceuticals, Inc Multiple System Atrophy Route of Administration Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous Intravenous/ Subcutaneous NA Oral Oral/intranasal/subcutaneous Parenteral Subcutaneous Multiple System Atrophy Molecule Type Multiple System Atrophy Products have been categorized under various Molecule types, such as Antibody Antisense oligonucleotides Immunotherapy Monoclonal antibody Peptides Protein Recombinant protein Small molecule Stem Cell Vaccine Multiple System Atrophy Pipeline Therapeutics Assessment Multiple System Atrophy Assessment by Product Type Multiple System Atrophy By Stage and Product Type Multiple System Atrophy Assessment by Route of Administration Multiple System Atrophy By Stage and Route of Administration Multiple System Atrophy Assessment by Molecule Type Multiple System Atrophy by Stage and Molecule Type DelveInsight's Multiple System Atrophy Report covers around 22+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Multiple System Atrophy product details are provided in the report. Download the Multiple System Atrophy pipeline report to learn more about the emerging Multiple System Atrophy therapies Some of the key companies in the Multiple System Atrophy Therapeutics Market include: Key companies developing therapies for Multiple System Atrophy are - Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others. Multiple System Atrophy Pipeline Analysis: The Multiple System Atrophy pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment. Multiple System Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Multiple System Atrophy drugs and therapies Multiple System Atrophy Pipeline Market Drivers Increased Awareness and Diagnosis, rising Genetic Research Activities are some of the important factors that are fueling the Multiple System Atrophy Market. Multiple System Atrophy Pipeline Market Barriers However, ethical and Practical Challenges in clinical trials, lack of Early and Specific Diagnostic Biomarkers, poor Understanding of Disease Mechanism and other factors are creating obstacles in the Multiple System Atrophy Market growth. Scope of Multiple System Atrophy Pipeline Drug Insight Coverage: Global Key Multiple System Atrophy Companies: Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others Key Multiple System Atrophy Therapies: NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers Request for Sample PDF Report for Multiple System Atrophy Pipeline Assessment and clinical trials Table of Contents 1. Multiple System Atrophy Report Introduction 2. Multiple System Atrophy Executive Summary 3. Multiple System Atrophy Overview 4. Multiple System Atrophy- Analytical Perspective In-depth Commercial Assessment 5. Multiple System Atrophy Pipeline Therapeutics 6. Multiple System Atrophy Late Stage Products (Phase II/III) 7. Multiple System Atrophy Mid Stage Products (Phase II) 8. Multiple System Atrophy Early Stage Products (Phase I) 9. Multiple System Atrophy Preclinical Stage Products 10. Multiple System Atrophy Therapeutics Assessment 11. Multiple System Atrophy Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Multiple System Atrophy Key Companies 14. Multiple System Atrophy Key Products 15. Multiple System Atrophy Unmet Needs 16 . Multiple System Atrophy Market Drivers and Barriers 17. Multiple System Atrophy Future Perspectives and Conclusion 18. Multiple System Atrophy Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name:DelveInsight Business Research LLP Contact Person: Ankit Nigam Email:Send Email Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
